|
Q4 2023
|
47 |
376,066 |
HROW, TGTX, SLRN, RYTM
|
13F-HR
|
2/14/2024 |
000149315224006653 |
|
Q3 2023
|
41 |
307,379 |
HROW, SLRN, OCUL, TGTX
|
13F-HR
|
11/14/2023 |
000149315223041364 |
|
Q2 2023
|
47 |
418,066 |
SLRN, HROW, OCUL, TELA
|
13F-HR
|
8/14/2023 |
000149315223028636 |
|
Q1 2023
|
41 |
333,877 |
HROW, OCUL, TELA, RYTM
|
13F-HR
|
5/15/2023 |
000149315223016769 |
|
Q4 2022
|
40 |
287,572 |
HROW, TELA, RYTM, OCUL
|
13F-HR
|
2/10/2023 |
000149315223004277 |
|
Q3 2022
|
42 |
242,132 |
HROW, OCUL, RYTM, TELA
|
13F-HR
|
11/14/2022 |
000149315222032068 |
|
Q2 2022
|
47 |
221,854 |
HROW, OCUL, CDXS, CRNX
|
13F-HR
|
8/15/2022 |
000149315222022856 |
|
Q1 2022
|
45 |
321,998 |
OCUL, CDXS, CMRX, HROW
|
13F-HR
|
5/16/2022 |
000149315222013764 |
|
Q4 2021
|
39 |
471,486 |
CDXS, OCUL, CMRX, CLDX
|
13F-HR
|
2/14/2022 |
000149315222004434 |
|
Q3 2021
|
48 |
535,390 |
OCUL, CLDX, CDXS, CMRX
|
13F-HR
|
11/15/2021 |
000149315221028799 |
|
Q2 2021
|
48 |
602,060 |
OCUL, CMRX, CLDX, BBIO
|
13F-HR
|
8/16/2021 |
000149315221020260 |
|
Q1 2021
|
58 |
680,804 |
OCUL, CMRX, TARA, BBIO
|
13F-HR
|
5/17/2021 |
000149315221012017 |
|
Q4 2020
|
59 |
765,570 |
OCUL, TARA, EIDOS THERAPEUTICS INC, ETON
|
13F-HR
|
2/12/2021 |
000149315221003697 |
|
Q3 2020
|
55 |
511,320 |
OCUL, TARA, ETON, CRDF
|
13F-HR
|
11/16/2020 |
000149315220021694 |
|
Q2 2020
|
48 |
495,150 |
TARA, OCUL, NLTX, CHEMOCENTRYX INC
|
13F-HR
|
8/14/2020 |
000149315220015902 |
|
Q1 2020
|
44 |
377,363 |
ARTARA THERAPEUTICS INC, FTSV, OCUL, APTO
|
13F-HR
|
5/15/2020 |
000149315220009140 |
|
Q4 2019
|
47 |
509,651 |
EPZM, APTO, CDXS, FTSV
|
13F-HR
|
2/14/2020 |
000149315220002529 |
|
Q3 2019
|
49 |
276,541 |
CDXS, STXS, EPZM, HROW
|
13F-HR
|
11/14/2019 |
000149315219017503 |
|
Q2 2019
|
43 |
328,094 |
CDXS, HROW, AXGN, EPZM
|
13F-HR
|
8/14/2019 |
000149315219012567 |
|
Q1 2019
|
53 |
361,134 |
CDXS, AXGN, EPZM, CERC
|
13F-HR
|
5/15/2019 |
000149315219007425 |
|
Q4 2018
|
47 |
267,975 |
CDXS, AXGN, LOXO, AMRN
|
13F-HR
|
2/14/2019 |
000149315219002114 |
|
Q3 2018
|
47 |
393,047 |
AXGN, CDXS, LOXO, AMRN
|
13F-HR
|
11/14/2018 |
000149315218016123 |
|
Q2 2018
|
36 |
386,358 |
AXGN, LOXO, CDXS, FGEN
|
13F-HR
|
8/14/2018 |
000149315218011830 |
|
Q1 2018
|
38 |
349,747 |
AXGN, BPMC, LOXO, CDXS
|
13F-HR
|
5/14/2018 |
000149315218006822 |
|
Q4 2017
|
35 |
312,298 |
AXGN, BPMC, FGEN, LOXO
|
13F-HR
|
2/9/2018 |
000149315218001743 |
|
Q3 2017
|
34 |
282,772 |
BPMC, AXGN, FGEN, IMMU
|
13F-HR
|
11/14/2017 |
000149315217013210 |
|
Q2 2017
|
41 |
239,398 |
BPMC, AXGN, FGEN, LOXO
|
13F-HR
|
8/14/2017 |
000149315217009239 |
|
Q1 2017
|
44 |
200,928 |
BPMC, AXGN, FGEN, NOVELION THERAPEUTICS INC
|
13F-HR
|
5/15/2017 |
000149315217005196 |
|
Q4 2016
|
40 |
169,717 |
BPMC, AXGN, ARIA, AEVI GENOMIC MEDICINE INC
|
13F-HR
|
2/21/2017 |
000114420417010166 |
|
Q3 2016
|
44 |
191,082 |
BPMC, AXGN, ARIA, MDGN
|
13F-HR
|
11/14/2016 |
000154692716000542 |
|
Q2 2016
|
49 |
149,709 |
AXGN, MDGN, ARIA, FGEN
|
RESTATEMENT
|
8/12/2016 |
000154692716000514 |
|
Q1 2016
|
52 |
160,362 |
AXGN, ARIA, RARE, FGEN
|
RESTATEMENT
|
5/27/2016 |
000154692716000499 |
|
Q4 2015
|
53 |
239,178 |
RARE, AXGN, FGEN, GERN
|
13F-HR
|
2/12/2016 |
000154692716000408 |
|
Q3 2015
|
49 |
203,221 |
CMRX, RARE, MLNT, AXGN
|
13F-HR
|
11/13/2015 |
000154692715000281 |
|
Q2 2015
|
46 |
251,326 |
CMRX, MLNT, TVTX, AMAG
|
13F-HR
|
8/14/2015 |
000154692715000231 |
|
Q1 2015
|
37 |
215,386 |
CMRX, MLNT, ARIA, TVTX
|
13F-HR
|
5/15/2015 |
000154692715000149 |
|
Q4 2014
|
36 |
197,898 |
CMRX, AGIO, MLNT, TVTX
|
13F-HR
|
2/13/2015 |
000154692715000070 |
|
Q3 2014
|
30 |
128,295 |
CMRX, PCYC, TVTX, ARIA
|
13F-HR
|
11/14/2014 |
000154692714000196 |
|
Q2 2014
|
27 |
115,981 |
CMRX, TVTX, ARIA, PCYC
|
13F-HR
|
8/14/2014 |
000154692714000159 |
|
Q1 2014
|
30 |
135,373 |
TVTX, ARIA, CMRX, PCYC
|
13F-HR
|
5/15/2014 |
000154692714000115 |
|
Q4 2013
|
23 |
127,387 |
GENTIUM S P A, GERN, PCYC, ARIA
|
13F-HR
|
2/14/2014 |
000154692714000060 |